## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

Transaction(s)

450,000

2

2

2

Bv 10X

I

T

I

T

Fund, L.P. (3)(4)(5)

By 10X

(3)(4)(5)

By 10X

(3)(4)(5)

By 10X

Fund, L.P. (3)(4)(5)

Fund, L.P.

Fund, L.P.

(Instr. 4)

\$2<sup>(2)</sup>

\$<mark>0</mark>(2)

\$0<sup>(2)</sup>

¢n(2)

OMB Number:	3235-0287
Estimated average bu	rden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

FORM 4

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person <sup>*</sup> CZIRR JAMES C					2. Issuer Name and Ticker or Trading Symbol PRO PHARMACEUTICALS INC [ PRWP.OB ]						3 (Chec	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner						
(Last) 425 JAN	`	irst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 05/13/2009							Officer (g below)	give title		Other (s below)	specify		
(Street) SANDPC (City)		) itate)	83864 (Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)					6. Indi Line) X	ividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person							
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
Date				caction 2A. Deemed Execution Date, if any (Month/Day/Year)			Code (Instr.						6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
								Code	v	Amoun	t	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)				(Instr. 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned         (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	vative Conversion Date Execution Date, Transaction Derivative F rity or Exercise (Month/Day/Year) if any Code (Instr. Securities (		Exp	5. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Am Securities Unde Derivative Secu (Instr. 3 and 4)			derlying curity	8. Price of Derivative Security (Instr. 5)	9. Numbo derivativ Securitie Beneficia Owned Followin Reported	re es ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)						

(D) Exer

Exercisable

(1)

05/13/2009

05/13/2009

05/13/2009

ouy)		
Explanation	of Response	es:

\$0.5

\$0.5

\$<mark>0.5</mark>

\$0.5

Series B-2

Convertible

Preferred

Warrant

(right to

Warrant

(right to

Warrants

(right to

huw)

buy) Series B

buy) Series A-2

Stock Series A-1

1. Each share of Series B-2 Convertible Preferred Stock is convertible into four shares of Issuer's common stock at a conversion price of \$0.50 per share (subject to customary anti-dilution protection adjustments) at the option of (a) the holder, at any time and (b) Issuer, at any time after February 12, 2010 (and upon 10 days notice) if the Issuer's common stock is quoted at or above \$1.50 per share for 15 consecutive trading days and an effective registration statement regarding the underlying shares of Issuer's common stock is in effect (subject to certain monthly volume limits). The shares of Series B-2 Convertible Preferred Stock do not expire.

2. On May 13, 2009, 10X Fund, L.P. purchased (a) 450,000 shares of Series B-2 Preferred Stock, (b) one Class A-1 Warrant to purchase 900,000 shares of Common Stock for \$0.50 per share, (c) one Class A-2 Warrant to purchase 900,000 shares of Common Stock for \$0.50 per share, and (d) one Class B Warrant to purchase 3,600,000 shares of Common Stock for \$0.50 per share, for aggregate consideration of \$900,000.

3. Reporting Person is a managing member of 10X Capital Management, LLC, a Florida limited liability company acting as the general partner of 10X Fund, L.P., a Delaware limited partnership, and as such, may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., such portion being equal to 10X Capital Management, LLC's (a) 20% interest in the profits of 10X Fund, L.P., (b) interest in any securities which are used to pay a 2% annual management fee to 10X Capital Management, LLC, and (c) interest in one-half of the Class B Warrants acquired by 10X Fund, L.P. in all closings other than the initial closing held on February 12, 2009, less one Class B Warrant which 10X Capital Management, LLC has committed to reallocate to investors in all prior closings until each such investor has one (1) additional Class B Warrant for each dollar invested.

4. Any such deemed indirect beneficial ownership may also be reduced by Mr. Czirr's proportional ownership in 10X Capital Management, LLC. Mr. Czirr disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

5. Excludes (i) up to 1,650,000 shares of Series B-2 Preferred Stock convertible into 6,600,000 shares of Common Stock; (ii) Class A-1 Warrants exercisable to purchase up to 3,300,000 shares of Common Stock; (iii) Class A-2 Warrants exercisable to purchase up to 3,300,000 shares of Common Stock; and (iv) Class B Warrants exercisable to purchase up to 13,200,000 shares of Common Stock; and (iv) Class B Warrants exercisable to purchase up to 13,200,000 shares of Common Stock; and (iv) Class B Warrants exercisable to purchase up to 13,200,000 shares of Common Stock; and (iv) Class B Warrants exercisable to purchase up to 13,200,000 shares of Common Stock; and (iv) Class B Warrants exercisable to purchase up to 13,200,000 shares of Common Stock; and (iv) Class B Warrants exercisable to purchase up to 13,200,000 shares of Common Stock; and (iv) Class B Warrants exercisable to purchase up to 13,200,000 shares of Common Stock; and (iv) Class B Warrants exercisable to purchase up to 13,200,000 shares of Common Stock; and (iv) Class B Warrants exercisable to purchase up to 13,200,000 shares of Common Stock; and (iv) Class B Warrants exercisable to purchase up to 13,200,000 shares of Common Stock; and (iv) Class B Warrants exercisable to purchase up to 13,200,000 shares of Common Stock; and (iv) Class B Warrants exercisable to purchase up to 13,200,000 shares of Common Stock; and (iv) Class B Warrants exercisable to purchase up to 13,200,000 shares of Common Stock; and (iv) Class B Warrants exercisable to purchase up to 13,200,000 shares of Common Stock; and (iv) Class B Warrants exercisable to purchase up to 13,200,000 shares of Common Stock; and (iv) Class B Warrants exercisable to purchase up to 13,200,000 shares of Common Stock; and (iv) Class B Warrants exercisable to purchase up to 13,200,000 shares of Common Stock; and (iv) Class B Warrants exercisable to purchase up to 13,200,000 shares of Common Stock; and (iv) Class B Warrants exercisable to purchase up to 13,200,000 shares of Common Stock; and (iv) Class B War

<u>James C. Czirr</u>	<u>05/18/2009</u>
** Signature of Reporting Person	Date

Amount or Number of

1,800,000

900,000

900,000

3,600,000

Shares

Expiration

(1)

05/13/2014

05/13/2014

05/13/2014

Date

Title

Comm

Stock

Common

Stock

Commo

Stock

Commo

Stock

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

05/13/2009

05/13/2009

05/13/2009

05/13/2009

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code V

P

P

P

р

(A)

450,000

1

1

1

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.